Cite
HARVARD Citation
Short, N. et al. (2022). Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American journal of hematology. 97 (6), pp. E201-E204. [Online].